Roxithromycin for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Presse medicale (Paris, France : 1983), 25(39), 1982-1988 (1996-12-14)
Macrolides, one of the oldest antibiotic classes, are widely used in out-patient, clinics and hospitals. The major improvement in developing newer derivatives concerns pharmacokinetic properties. Increased half-lives, persisting concentrations in tissues, interstitial fluids and macrophages confer upon newer macrolides significant
Analytical and bioanalytical chemistry, 412(1), 203-222 (2019-12-06)
This study examines an improved and simplified method for solid-phase extraction (SPE), which offers rapid and accurate determination and identification of 44 pharmaceutically active compounds using ultra-performance liquid chromatography (UPLC) and tandem mass spectrometry (MS/MS). The common active compounds include
Journal of chemotherapy (Florence, Italy), 3 Suppl 1, 33-35 (1991-01-01)
The usefulness of macrolides in treating respiratory infections has been established for over thirty years. Currently, a great deal of interest is being focused on roxithromycin, a new semisynthetic derivative of erythromycin which is more stable than erythromycin under acidic
[Roxithromycin (Forilin, Surlid)].
N H Eriksen et al.
Ugeskrift for laeger, 152(6), 411-412 (1990-02-05)
Roxithromycin is a derivative of the macrolide antibacterial erythromycin with in vitro antibacterial activity resembling that of the parent compound. The drug has activity against some Staphylococcus spp., many Streptococcus spp., Moraxella (Branhamella) catarrhalis, Mycoplasma pneumoniae, Legionella pneumophila and Chlamydia
